Our new discovery research strategy aims at further enhancing our capacity for innovation and at encouraging scientific creativity for diseases with high unmet medical need. It is based on three pillars:
Four Discovery Research Therapeutic Areas
Build on our strengths in R&D by focusing on core diseases for which we have built expertise over time and are actively investing from early research, through clinical development, to the market phase.
Focus on highly dynamic research fields such as immune modulation and regenerative medicine which may impact and create synergies among several of our Discovery Research Therapeutic Areas.
Research Beyond Borders
Explore emerging science and technology for but also beyond our Discovery Research Therapeutic Areas in order to prepare a timely and efficient entry into emerging new medical and scientific fields and technologies.
Immunology and Respiratory Research
Boehringer Ingelheim is one of the leading pharmaceutical companies worldwide in the treatment of respiratory diseases.
It has been recognized that respiratory diseases such as COPD or Asthma are heterozygous syndromes that are often associated with an aberrant immune response of the afflicted patient. Therefore it made sense to create a new Discovery Research Therapeutic Area that combines our long-standing competence and success story in respiratory diseases with our expertise in immunology.
Within this newly formed department, more than 200 scientists work in our fully integrated drug discovery centre of excellence for Immunology and Respiratory Diseases research at sites in Biberach, Germany and Ridgefield, CT, USA.